Nodding Xianshi, founded by a seasoned team with extensive experience in the healthcare industry, is dedicated to building a globally leading, AI-precision-driven platform for non-invasive, non-metabolic intervention ultrasound body shaping and repair. It focuses on high-growth areas such as helping humans resist skin aging, alter body contours, and ablate redundant fat.
Nodding Xianshi's core technology platform aims to integrate multiple modules, including 3D individualized energy planning for body shaping, AI-assisted precise guidance, non-invasive superficial ultrasound ablation, and plastic data tracking and management. The platform's capabilities, such as high-precision ultrasound imaging, AI algorithm-assisted diagnosis, and personalized treatment path planning, can significantly enhance the precision and operational standardization of skin treatments and body contouring procedures in medical aesthetic institutions. This reduces reliance on physician experience and enables closed-loop management encompassing "diagnosis-assessment-treatment-follow-up" within the medical aesthetic context.
The hallmark of the Nodding Xianshi product platform is its non-invasive, multi-layered, plannable, and precise immediate shaping capabilities. Through efficient pre-operative simulation planning, precise intra-operative energy delivery, and post-operative quantitative tracking—forming a full-cycle, precise closed-loop management system—Nodding Xianshi will enable each case of skin improvement and body shaping need to achieve ideal target outcomes more rapidly, without the need for dietary control or pharmaceutical intervention. Furthermore, leveraging AI technology and its existing integrated ultrasound diagnosis and treatment platform, Nodding Xianshi will actively expand integrated diagnosis and treatment solutions using ultrasound image-guided ultrasound ablation into various application scenarios, such as thyroid nodule ablation.
The introduction of AI technology is fundamentally reshaping the usage and clinical value of ultrasound devices: Firstly, AI systems can provide real-time prompts for standard scanning planes, automatically measure parameters, and assess image quality during ultrasound examinations, significantly reducing dependence on operator experience and enhancing the service capabilities of primary care institutions. Secondly, by integrating patient imaging, medical history, and clinical data, AI can assist in generating personalized treatment recommendations, particularly in medical aesthetics, enabling an intelligent full process of "skin condition assessment - treatment parameter recommendation - efficacy prediction - post-operative follow-up." Thirdly, the combination of AI and robotics has already enabled the separation of remote ultrasound scanning from diagnosis; experts can perform diagnostics in the cloud while primary operators need only conduct standardized scans, addressing the uneven distribution of medical resources. Finally, AI can fuse ultrasound images with clinical data to build efficacy prediction models, enabling dynamic efficacy assessment and protocol optimization in scenarios like tumor ablation, skin treatment, and fat management.
Currently, Nodding Xianshi's first product has completed engineering prototype development and is soon enter the registration clinical trial phase. It is expected to apply for NMPA Class III medical device registration in 2026. Over the next five years, the company plans to apply for Class III indications targeting needs in body contouring, fat management, collagen repair, skin improvement, and ultrasound-guided surgical treatment systems. It aims to launch several segmented, integrated AI ultrasound diagnosis and treatment devices and simultaneously advance FDA certification to expand into overseas markets.
It is reported that Mike Fund, the lead investor in this round, is a private equity firm focusing on healthcare, frontier technology, consumer sectors, and other areas. Its investment in Nodding Xianshi also reflects its high recognition of the application prospects for AI+ medical imaging equipment in consumer healthcare settings.
A relevant official from the institutions involved in this round of investment stated: "As consumers increasingly demand standardization, safety, and consistent results in medical aesthetics, traditional experience-dependent treatment methods can no longer fully meet market demands. The Nodding Xianshi team possesses profound medical industry background and clinical translation experience. Its technological approach and business model for the AI ultrasound platform both demonstrate significant differentiated advantages. We believe Nodding Xianshi has the potential to become one of the first companies in China to achieve large-scale implementation of AI ultrasound diagnosis and treatment equipment in the medical aesthetics field."
